NO962346L - Humaniserte antistoffer og anvendelser derav - Google Patents

Humaniserte antistoffer og anvendelser derav

Info

Publication number
NO962346L
NO962346L NO962346A NO962346A NO962346L NO 962346 L NO962346 L NO 962346L NO 962346 A NO962346 A NO 962346A NO 962346 A NO962346 A NO 962346A NO 962346 L NO962346 L NO 962346L
Authority
NO
Norway
Prior art keywords
antibodies
humanized antibodies
islets
bound
preparation
Prior art date
Application number
NO962346A
Other languages
English (en)
Norwegian (no)
Other versions
NO962346D0 (no
Inventor
Yee-Tharn Augustine Lin
Original Assignee
T Cell Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Cell Sciences Inc filed Critical T Cell Sciences Inc
Publication of NO962346D0 publication Critical patent/NO962346D0/no
Publication of NO962346L publication Critical patent/NO962346L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO962346A 1993-12-08 1996-06-05 Humaniserte antistoffer og anvendelser derav NO962346L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939325182A GB9325182D0 (en) 1993-12-08 1993-12-08 Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
PCT/IB1994/000387 WO1995016038A2 (en) 1993-12-08 1994-11-21 Humanized antibodies and uses thereof

Publications (2)

Publication Number Publication Date
NO962346D0 NO962346D0 (no) 1996-06-05
NO962346L true NO962346L (no) 1996-08-06

Family

ID=10746330

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962346A NO962346L (no) 1993-12-08 1996-06-05 Humaniserte antistoffer og anvendelser derav

Country Status (24)

Country Link
US (1) US5861155A (lv)
EP (1) EP0737250A1 (lv)
JP (1) JPH09509307A (lv)
KR (2) KR100239607B1 (lv)
CN (1) CN1063792C (lv)
AU (1) AU699249B2 (lv)
BR (1) BR9408278A (lv)
CA (1) CA2178622A1 (lv)
CZ (2) CZ287347B6 (lv)
EE (1) EE03271B1 (lv)
FI (1) FI962377A (lv)
GB (1) GB9325182D0 (lv)
HU (1) HUT75553A (lv)
IL (1) IL111926A (lv)
LV (1) LV11631B (lv)
NO (1) NO962346L (lv)
NZ (1) NZ276170A (lv)
PL (1) PL180157B1 (lv)
RU (1) RU2139934C1 (lv)
SG (1) SG48420A1 (lv)
SK (1) SK73596A3 (lv)
UA (1) UA29494C2 (lv)
WO (1) WO1995016038A2 (lv)
ZA (1) ZA949341B (lv)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
CN1064052C (zh) * 1997-09-29 2001-04-04 中国科学院微生物研究所 甲状旁腺素相关蛋白人源化抗体及其制备方法
WO1999037329A1 (en) * 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
GB9906233D0 (en) * 1999-03-19 1999-05-12 Univ Newcastle Bone formation
US20030175972A1 (en) * 2000-10-20 2003-09-18 Daley George Q. Expression vectors and uses thereof
US20060233790A1 (en) * 2002-03-22 2006-10-19 Shiroh Futaki Immunoglobulin/hydrophilic peptide complexes
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
GB0302740D0 (en) * 2003-02-06 2003-03-12 Axis Shield Asa Assay
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
NZ550816A (en) * 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2006137354A1 (ja) * 2005-06-21 2006-12-28 Medical & Biological Laboratories Co., Ltd. アミロイド線維形成に対する阻害活性を有する抗体
KR100740201B1 (ko) * 2005-10-21 2007-07-18 삼성전자주식회사 듀얼 전송 스트림 생성 장치 및 그 방법
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
WO2007125089A2 (en) * 2006-04-28 2007-11-08 ETH Zürich Antibodies for the detection of bacillus anthracis and vaccine against b. anthracis infections
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
CN101505795B (zh) 2006-07-03 2013-02-13 查尔斯·戴维·阿代尔 用于调节细胞粘附分子表达的组合物
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
SI2087002T1 (sl) * 2006-10-27 2014-11-28 Lpath, Inc. Sestavki in postopki za vezavo sfingozin-1-fosfata
AU2008260135A1 (en) 2007-05-30 2008-12-11 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
AU2008287555A1 (en) 2007-08-10 2009-02-19 Agency For Science, Technology And Research (A*Star) VHZ for diagnosis and treatment of cancer
EP2201040A1 (en) * 2007-09-24 2010-06-30 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
CN102176914B (zh) * 2008-08-08 2014-12-17 新加坡科技研究局 用于诊断和治疗癌症的vhz
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
EP2370092A1 (en) 2008-12-03 2011-10-05 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
AU2009322185A1 (en) * 2008-12-05 2011-07-21 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
WO2010098863A1 (en) * 2009-02-26 2010-09-02 Lpath, Inc. Humanized platelet activating factor antibody design using anti-lipid antibody templates
EP2419446A4 (en) * 2009-04-17 2013-01-23 Lpath Inc HUMANIZED ANTIBODY COMPOSITIONS AND METHOD FOR BINDING LYSOPHOSPHACIDIC ACID
EP2536761B1 (en) 2010-02-19 2017-09-20 The Board Of Regents Of The University Of Oklahoma Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
RU2603097C2 (ru) 2010-12-21 2016-11-20 Селексис Фармасьютикалс Корпорейшн Антитела к р-селектину и способы их применения и идентификации
US9217040B2 (en) 2011-01-14 2015-12-22 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
WO2012129520A1 (en) 2011-03-24 2012-09-27 Texas Tech University System Tcr mimic antibodies as vascular targeting tools
WO2012158989A2 (en) 2011-05-19 2012-11-22 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
HUE039009T2 (hu) 2011-08-05 2018-12-28 Res Found Dev Javított eljárások és készítmények Olfml3-mediált angiogenesis modulálására
EP3718556A3 (en) 2012-08-31 2020-12-30 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
AU2013312529A1 (en) 2012-09-05 2015-04-16 The University Of Birmingham Target peptides for colorectal cancer therapy and diagnostics
US9803014B2 (en) 2012-10-24 2017-10-31 Research Development Foundation JAM-C antibodies and methods for treatment of cancer
US20160000893A1 (en) 2012-12-13 2016-01-07 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
EP3639841B1 (en) 2013-03-27 2023-09-06 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
US9914775B2 (en) 2013-08-21 2018-03-13 The Board Of Regents Of The University Of Texas System Methods for treating inflammatory disorders or cancer metastasis by administering antibodies to connexin 43 (Cx43) hemichannels
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
CN114470194A (zh) 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
CA3015839A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System Connexin (cx)43 hemichannel-binding antibodies and uses thereof
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2
EP3436481B1 (en) 2016-03-29 2021-06-30 Stcube, Inc. Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
KR20190031299A (ko) 2016-07-20 2019-03-25 주식회사 에스티큐브 글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
CN110662760A (zh) 2017-05-12 2020-01-07 奥古斯塔大学研究所公司 人甲胎蛋白特异性t细胞受体及其用途
US20200131266A1 (en) 2017-05-31 2020-04-30 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
AU2018277838A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
EP3625254B1 (en) 2017-07-31 2023-12-13 F. Hoffmann-La Roche AG Three-dimensional structure-based humanization method
US11464784B2 (en) 2017-09-15 2022-10-11 The Regents Of The University Of California Inhibition of aminocylase 3 (AA3) in the treatment of cancer
WO2019195561A2 (en) 2018-04-06 2019-10-10 BioLegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
WO2019209995A2 (en) 2018-04-25 2019-10-31 Precision Ibd, Inc. Optimized anti-tl1a antibodies
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2020068557A1 (en) 2018-09-25 2020-04-02 BioLegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
EP4219550A1 (en) 2018-11-02 2023-08-02 Oklahoma Medical Research Foundation Monoclonal antibodies to eltd1 and uses thereof
AU2020226904A1 (en) * 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
GB2599229B (en) * 2019-02-21 2024-04-24 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN114127112A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
JP2022549504A (ja) 2019-09-26 2022-11-25 エスティーキューブ アンド カンパニー グリコシル化ｃｔｌａ－４に対して特異的な抗体およびその使用方法
US20220356248A1 (en) 2019-10-09 2022-11-10 Stcube & Co Antibodies specific to glycosylated lag3 and methods of use thereof
BR112022007720A2 (pt) 2019-10-24 2022-08-23 Prometheus Biosciences Inc Anticorpos humanizados para ligante 1a tnf-like (tl1a) e seus usos
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
WO2021146383A1 (en) 2020-01-17 2021-07-22 BioLegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same
EP4107173A1 (en) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
JP2023523011A (ja) 2020-04-24 2023-06-01 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2021333779A1 (en) 2020-08-26 2023-04-13 Marengo Therapeutics, Inc. Methods of detecting TRBC1 or TRBC2
JP2023542080A (ja) 2020-08-26 2023-10-05 マレンゴ・セラピューティクス，インコーポレーテッド カルレティキュリンに結合する多機能性分子およびその使用
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
JP2023551535A (ja) 2020-12-01 2023-12-08 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｔ細胞がんを治療するための方法および材料
BR112023020832A2 (pt) 2021-04-08 2023-12-19 Marengo Therapeutics Inc Moléculas multifuncionais ligadas a tcr e seus usos
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
DE68909441T2 (de) * 1988-02-12 1994-02-10 British Tech Group Modifizierte Antikörper.
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
KR100216097B1 (ko) * 1989-07-19 1999-08-16 크리스토퍼 제이. 마골린 자가면역 및 악성종양질환 치료제로서의 t세포 수용체 펩티드
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5067193A (en) * 1990-07-26 1991-11-26 Container Graphics Corporation Rotary printing plate washing apparatus
US5445940A (en) * 1991-08-28 1995-08-29 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease

Also Published As

Publication number Publication date
NZ276170A (en) 1998-05-27
LV11631A (lv) 1996-12-20
LV11631B (en) 1997-04-20
CA2178622A1 (en) 1995-06-15
CZ162896A3 (en) 1997-01-15
CZ287347B6 (en) 2000-10-11
SK73596A3 (en) 1997-05-07
KR960706560A (ko) 1996-12-09
CN1063792C (zh) 2001-03-28
AU1033395A (en) 1995-06-27
IL111926A0 (en) 1995-03-15
PL180157B1 (en) 2000-12-29
CN1142855A (zh) 1997-02-12
BR9408278A (pt) 1996-12-17
NO962346D0 (no) 1996-06-05
EP0737250A1 (en) 1996-10-16
RU2139934C1 (ru) 1999-10-20
ZA949341B (en) 1996-05-24
HUT75553A (en) 1997-05-28
AU699249B2 (en) 1998-11-26
FI962377A (fi) 1996-07-30
KR100258902B1 (en) 2000-06-15
CZ287298B6 (cs) 2000-10-11
HU9601574D0 (en) 1996-07-29
EE03271B1 (et) 2000-06-15
US5861155A (en) 1999-01-19
WO1995016038A3 (en) 1995-07-06
WO1995016038A2 (en) 1995-06-15
IL111926A (en) 2002-07-25
FI962377A0 (fi) 1996-06-07
KR100239607B1 (ko) 2000-01-15
JPH09509307A (ja) 1997-09-22
PL314908A1 (en) 1996-09-30
GB9325182D0 (en) 1994-02-09
SG48420A1 (en) 1998-04-17
UA29494C2 (uk) 2000-11-15

Similar Documents

Publication Publication Date Title
NO962346L (no) Humaniserte antistoffer og anvendelser derav
CA2091769A1 (en) Framework mutated antibodies and their preparation
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
AU7095887A (en) Human gamma interferon-specific receptor protein, antibody against said protein and said antibody and compositions containing said protein and antibody
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
CA2128511A1 (en) Monomeric and dimeric antibody-fragment fusion proteins
EP0687183A4 (en) SYNERGISTIC COMPOSITION OF A CD4-BASED PROTEIN AND ANTIBODY AGAINST HIV-1, AND METHODS OF USE
SE8605295D0 (sv) Monoclonal antibodies cross-reactive and crossprotective against p. aeruginosa serotypes
DK113389D0 (da) Monoklonale antistoffer
DK1003552T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
ES2009140A6 (es) Un metodo de produccion de anticuerpos monoclonales humanos de proteccion cruzada y de composiciones que los contienen.
FI945865A (fi) Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita
NO922621L (no) Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav
ATE164311T1 (de) Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten
DK0687300T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
ES2013321A6 (es) Un metodo de produccion de anticuerpos monoclonales
DK0852623T3 (da) Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
FI960839A (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
CA2262546A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
AU1875592A (en) Amino acid sequence of anticancer human monoclonal antibody and dna base sequence coding for the same
IL130960A0 (en) Novel ifn receptor 1 binding proteins dna encoding them and methods of modulating cellular response to interferons
AU2328788A (en) Preparation containing high molecular staphylococcal protein; antibody preparation directed against the protein; and the use of the preparations
IL80918A (en) Monoclonal antibodies cross-reactive and cross-protective against p.aeruginosa serotypes and pharmaceutical compositions and kits containing said antibodies
RU94026276A (ru) Рецепторы интерлейкина-12 и антител

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application